The decrease in CarnoSyn ® beta-alanine royalty, licensing, and raw material sales revenue during the second quarter of fiscal 2025 was primarily due to a decrease in orders from existing customers.
The U.S. Food and Drug Administration could soon assist American consumers in reaching better health. A recent proposal from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback